1,766 Shares in Repligen Co. (NASDAQ:RGEN) Acquired by Diversify Advisory Services LLC

Diversify Advisory Services LLC bought a new position in Repligen Co. (NASDAQ:RGENFree Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,766 shares of the biotechnology company’s stock, valued at approximately $323,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Glenmede Trust Co. NA increased its holdings in Repligen by 24.2% in the 3rd quarter. Glenmede Trust Co. NA now owns 3,791 shares of the biotechnology company’s stock worth $603,000 after acquiring an additional 739 shares in the last quarter. WealthPlan Investment Management LLC purchased a new stake in Repligen in the 3rd quarter worth approximately $210,000. Townsquare Capital LLC increased its holdings in Repligen by 12.0% in the 3rd quarter. Townsquare Capital LLC now owns 9,464 shares of the biotechnology company’s stock worth $1,505,000 after acquiring an additional 1,013 shares in the last quarter. Diversified Trust Co increased its holdings in Repligen by 35.4% in the 3rd quarter. Diversified Trust Co now owns 4,291 shares of the biotechnology company’s stock worth $682,000 after acquiring an additional 1,123 shares in the last quarter. Finally, Comerica Bank boosted its stake in Repligen by 1,259.1% in the 3rd quarter. Comerica Bank now owns 115,929 shares of the biotechnology company’s stock worth $18,434,000 after purchasing an additional 107,399 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Down 0.6 %

NASDAQ RGEN opened at $120.08 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35. The company has a market capitalization of $6.71 billion, a P/E ratio of 480.34, a P/E/G ratio of 4.02 and a beta of 0.95. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The stock has a 50 day moving average price of $147.23 and a 200-day moving average price of $171.91.

Repligen (NASDAQ:RGENGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter in the previous year, the company posted $0.64 EPS. The business’s quarterly revenue was down 17.1% on a year-over-year basis. As a group, equities analysts predict that Repligen Co. will post 1.46 EPS for the current fiscal year.

Insider Activity at Repligen

In related news, Director Martin D. Madaus purchased 1,615 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were bought at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the acquisition, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Repligen news, Director Martin D. Madaus bought 1,615 shares of Repligen stock in a transaction on Friday, June 14th. The shares were acquired at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the purchase, the director now directly owns 4,613 shares in the company, valued at approximately $576,348.22. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Anthony Hunt bought 2,000 shares of Repligen stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the purchase, the chief executive officer now owns 165,177 shares of the company’s stock, valued at $20,495,162.16. The disclosure for this purchase can be found here. 1.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on RGEN shares. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. JPMorgan Chase & Co. dropped their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Finally, Guggenheim started coverage on Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $193.00.

Get Our Latest Research Report on RGEN

About Repligen

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.